# Georgios Sopasis, BSc (Hons) 
### Pharmaceutical Regulatory Affairs | Former Doctoral Researcher (Inorganic Chemistry)
[![TGA Compliance](https://img.shields.io/badge/Compliance-TGA%20%2F%20EMA-blue)](https://www.tga.gov.au/)
[![Expertise](https://img.shields.io/badge/Expertise-ICH%20Q3D%20%26%20Stability-green)](#)
[![Methodology](https://img.shields.io/badge/Methodology-eCTD%20%2F%20QRM-orange)](#)

---

## üöÄ Professional Profile
I am a **Materials Scientist** transitioning into **Regulatory Affairs**, bridging the gap between high-level laboratory research and global market authorisation. My background includes 3+ years of doctoral-level research in **Alzheimer‚Äôs pharmacology** and small-molecule inorganic synthesis. 

I specialise in the **Regulatory Frame**: utilising risk-based justifications and data-driven strategies to expedite market entry for complex drug products.

---

## üìÅ Featured Project: Amoxicillin Suspension ARTG Registration
This project demonstrates the transition of a legacy generic product into the Australian market, addressing critical compliance gaps through the eCTD framework.

### üìã Project Strategic Overview
| Component | Status | Regulatory Action |
| :--- | :--- | :--- |
| **Submission Category** | Category 1 | New Generic Medicine (Section 23) |
| **Quality Gap (ICH Q3D)** | Identified | Remediated via ICP-MS Quantitative Analysis |
| **Stability Gap (Zone IVb)** | Mitigation | 12-Month Shelf Life Commitment + Post-Approval Variation |
| **GMP Evidence** | Validated | MRA/CV Pathway (AIFA Italy to TGA Australia) |

### üõ†Ô∏è Key Regulatory Skills Demonstrated
* **Administrative Strategy (M1):** Drafting TGO 91-compliant labeling, S4 Poison Scheduling, and Biowaiver justifications.
* **Scientific Authority (M2.3):** Developing Quality Overall Summaries (QOS) based on physicochemical properties (Zeta Potential, Rheology, pH Buffering).
* **Digital Literacy:** Mastery of eCTD hierarchy and AI-augmented regulatory drafting for maximum efficiency.

---

## üî¨ Technical Toolkit
| Category | Expertise |
| :--- | :--- |
| **Analytical** | ICP-MS, HPLC, NMR, LC-MS, Particle Size Distribution, FTIR, XAS, XFM |
| **Regulatory** | eCTD, ICH Q3D/Q9/Q1, TGO 91/100, SUSMP Scheduling |
| **Therapeutic** | Antimicrobials, NTI Drugs, Alzheimer's Pharmacology, |
| **Digital** | GitHub Portfolio Management, Cloud Computing, AI-Driven Documentation, LORENZ docuBridge (Mock) |

---

## üß™ Doctoral Research Background (Inorganic chemistry)
During my tenure as a **Doctoral Researcher**, I focused on the synthesis of novel inhibitors for Alzheimer‚Äôs disease. My work resulted in:
* The synthesis of pharmaceutical agents currently utilised in ongoing peer-reviewed research.
* Study of the kinetics of copper and zinc in the brain of Alzheimer's disease models. 
* Mastery of the "Critical Quality Attribute" mindset from the bench-top level up.

---

## üì´ Connect with Me
- **LinkedIn:** www.linkedin.com/in/george-sopasis(#)
- **Location:** Malvern, VIC, Australia
- **Email:** sopasis@gmail.com(#)
